Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV
NCT07054931Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv4, Teropavimab, zinlirvimab in human immunodeficiency virus infection (HIV), sponsored by University of Oxford. Started Sep 2025; status: recruiting.
02
Drugs
ChAdOx1.tHIVconsv1ChAdOx1.HIVconsv62MVA.tHIVconsv4Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07054931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054931.